insure persons past 35 against fear of the feeling of advancing age; and to help build new, red blood, which were the conditions and purposes for which the article was offered in the September 21, 1952, issue of a local newspaper. The article was misbranded in this respect when introduced into, while in, and while held for sale after shipment in, interstate commerce.

DISPOSITION: January 23, 1953. Default decree of condemnation. The court ordered that the product be delivered to the hospital ward of a Federal institution, for use in the treatment of patients requiring the prescribing of vitamin preparations.

DRUGS AND DEVICES ACTIONABLE BECAUSE OF DEVIATION FROM OFFICIAL OR OWN STANDARDS

4049. Adulteration and misbranding of conjugated estrogen tablets. U. S. v. 3 Bottles, etc. (F. D. C. No. 33586. Sample Nos. 41220–L, 41221–L.)

LIBEL FILED: September 12, 1952, Western District of Washington.

ALLEGED SHIPMENT: On various dates from outside the State of Washington.

PRODUCT: 3 500-tablet bottles of *No. 105 conjugated estrogen tablets* and 5 500-tablet bottles and 2 1,000-tablet bottles of *No. 106 conjugated estrogen tablets* at Seattle, Wash.

Analysis showed that the *No. 105 conjugated estrogen tablets* and the *No. 106 conjugated estrogen tablets* contained 0.94 milligram and 0.475 milligram, respectively, per tablet of conjugated estrogens expressed as sodium estrone sulfate.

LABEL, IN PART: (Bottle) "No. 105 1.25 mg. [or "No. 106 0.625 mg."] Estrogenic Substances (Water-Soluble) Conjugated Estrogens (Equine) Each tablet contains 1.25 mg. [or "0.625 mg."] of estrogens in their naturally occurring, water-soluble conjugated form, expressed as sodium estrone sulfate. Distributed by Palmer & Co. Seattle, Wash."

NATURE OF CHARGE: Adulteration, Section 501 (c), the strength of the *No. 105 conjugated estrogen tablets* and the *No. 106 conjugated estrogen tablets* differed from that which they purported and were represented to possess.

Misbranding, Section 502 (a), the label statements "Each tablet contains 1.25 mg. of estrogens in * * * conjugated form, expressed as sodium estrone sulfate" and "Each tablet contains 0.625 mg. of estrogens in * * * conjugated form, expressed as sodium estrone sulfate," respectively, were false and misleading as applied to the tablets, which contained less than the declared amounts of estrogens in conjugated form.

DISPOSITION: April 3, 1953. Default decree of condemnation and destruction.

4050. Adulteration and misbranding of vitamin B complex capsules. U. S. v. 700 Capsules, etc. (F. D. C. No. 34539. Sample No. 56845–L.)

LIBEL FILED: January 7, 1953, Northern District of Ohio.

ALLEGED SHIPMENT: On or about September 29, 1952, by Fellows Medical Mfg. Co., Inc., from New York, N. Y.

PRODUCT: *Vitamin B complex capsules.* 700 capsules and 32 bottles, each bottle containing 50 capsules, at Cleveland, Ohio. Analysis showed that the product contained approximately 76 percent of the declared amount of vitamin B_1.

LABEL, IN PART: "Fellows * * * Vitamin B-Complex Capsules Each Capsule Contains * * * Thiamine Hydrochloride (10 M. D. R.) 10 Mg. * * * Therapeutic."